AbbVie (ABBV) Non-Current Deferred Tax Liability (2012 - 2026)

AbbVie (ABBV) has 15 years of Non-Current Deferred Tax Liability data on file, last reported at $2.3 billion in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 9.68% year-over-year to $2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (down 9.68% YoY) and the FY2025 annual result came in at $2.4 billion, down 20.07% from the prior year.
• Non-Current Deferred Tax Liability retreated to $2.3 billion in Q1 2026 per ABBV's latest filing, from $2.4 billion in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $4.7 billion in Q4 2022 and bottomed at $2.0 billion in Q3 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $2.6 billion (2025), against an average of $2.6 billion.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability sank 45.25%; it then surged 34.49% in 2024.
• Tracing ABBV's Non-Current Deferred Tax Liability over 5 years: stood at $4.7 billion in 2022, then slumped by 43.53% to $2.7 billion in 2023, then grew by 12.58% to $3.0 billion in 2024, then slipped by 20.07% to $2.4 billion in 2025, then declined by 2.39% to $2.3 billion in 2026.
• Per Business Quant, the three latest ABBV Non-Current Deferred Tax Liability figures stand at $2.3 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.5 billion (Q3 2025).

Peer Comparison